Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Recipient : Jiangsu Hengrui Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Hengrui’s Heng Qin Eye Drops Approved As First MGD-Linked Dry Eye Therapy
Details : Heng Qin (perfluorohexyloctane) eye drops is approved for the treatment of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD).
Product Name : Heng Qin
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 08, 2025
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Recipient : Jiangsu Hengrui Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Novaliq Receives Positive CHMP Opinion for Vevizye® in Dry Eye Disease
Details : Vevizye is a clear ciclosporin 0.1% solution, free of oils, surfactants, and preservatives. It is indicated for the treatment of moderate to severe dry eye disease.
Product Name : CyclASol
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
July 29, 2024
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cyclosporine is a Peptide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dry Eye Syndromes.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
March 26, 2024
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CyclASol (cyclosporine) solubilized in a novel water-free excipient, perfluorobutylpentane, it is specifically developed as a potent and comfortable anti-inflammatory dry eye drug therapy with rapid onset of effect for dry eye patients.
Product Name : CyclASol
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
August 24, 2023
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Harrow
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Through acquisition, Harrow gains U.S. and Canadian commercial rights for Vevye (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, ophthalmic solution prescription drug based on Novaliq’s proprietary EyeSol® water-free technology.
Product Name : CyclASol
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
July 17, 2023
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Harrow
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : SENJU PHARMACEUTICAL CO LTD
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Senju acquires Japan rights to develop, manufacture, and commercialize NOV03 (perfluorohexyloctane ophthalmic solution), the first and only prescription treatment for signs and symptoms of dry eye disease that directly targets tear e...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 13, 2023
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : SENJU PHARMACEUTICAL CO LTD
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vevye (cyclosporine ophthalmic solution) is solubilized in a novel and was designed to address unmet needs, providing patients with a fast acting and well tolerable dry eye drug therapy.
Product Name : CyclASol
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
June 08, 2023
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Recipient : Bausch & Lomb Incorporated
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Miebo (perfluorohexyloctane) is the first drug approved by USFDA to treat dry eye disease associated with Meibomian gland dysfunction. It stabilizes the lipid layer for hours to protect the tear film and has the ability to penetrate the Meibomian glands.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 18, 2023
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Recipient : Bausch & Lomb Incorporated
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CyclASol® consists of cyclosporine solubilized in a novel water-free excipient, perfluorobutylpentane , it is specifically developed as a potent and comfortable anti-inflammatory dry eye drug therapy with rapid onset of effect for dry eye patients.
Product Name : CyclASol
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
February 08, 2023
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Recipient : Bausch & Lomb Incorporated
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NOV03 (Perfluorohexyloctane) is the first drug developed to treat dry eye disease associated with Meibomian gland dysfunction in a highly effective way. It stabilizes the lipid layer for hours to protect the tear film and has the ability to penetrate the...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 04, 2023
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Recipient : Bausch & Lomb Incorporated
Deal Size : Inapplicable
Deal Type : Inapplicable